Cover Image

Adoptive T cell as a strategy for targeted delivery of immune checkpoint therapy

Saved in:

Bibliographic Details
Main Authors:	J. Sung (Author), B.D. Walker (Author), M. Clohosey (Author), J. Kirchherr (Author), Y. Xu (Author), J. Warren (Author), N. Archin (Author), N. Goonetilleke (Author), D. Margolis (Author)
Format:	Book
Published:	Elsevier, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A modified viral outgrowth assay incorporating ultra-sensitive P24 measurements
by: N. Archin, et al.
Published: (2017)

Defining the landscape of HIV-specific T-cell responses in HIV-1 infected durably suppressed participants
by: J. Warren, et al.
Published: (2017)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

HIV-1 in the latent reservoir is largely sensitive to circulating T cells
by: J. Warren, et al.
Published: (2019)

CD8 T cells from HIV positive individuals on ART have a skewed differentiation phenotype and impaired proliferative responses
by: G. Clutton, et al.
Published: (2017)

Induction of HIV from latency by a novel molecule
by: N.M. Archin, et al.
Published: (2015)

Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
by: Ryunosuke Hoshi, et al.
Published: (2024)

PP 1.24 - 00132 BET PROTACS Reveal BRD4 Disruption of the 7SK/P-TEFb Equilibrium is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells
by: A-M. Turner, et al.
Published: (2022)

Enhancing personalized immune checkpoint therapy by immune archetyping and pharmacological targeting
by: Claudia Cerella, et al.
Published: (2023)

The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection
by: C. Gay, et al.
Published: (2019)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
by: Zou W, et al.
Published: (2021)

Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies
by: Chih Kit Chung, et al.
Published: (2022)

The role of immune checkpoints in cardiovascular disease
by: Laura I. Yousif, et al.
Published: (2022)

Factors Associated with Adoption of Immune Checkpoint Inhibitor Treatment for Advanced Melanoma: A SEER-Medicare Cohort Study
by: Cassandra Mohr, et al.
Published: (2024)

Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
by: Gian Marco Leone, et al.
Published: (2023)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
by: Diederick J. van Doorn, et al.
Published: (2020)

The Strategies and Mechanisms of Immune Checkpoint Inhibitors for Brain Metastases in NSCLC
by: Ji Li, et al.
Published: (2022)

The Glycosylation of Immune Checkpoints and Their Applications in Oncology
by: Linlin Zheng, et al.
Published: (2022)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021)

Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development
by: Seyed Hossein Kiaie, et al.
Published: (2021)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
by: Yihao Wu, et al.
Published: (2023)

27 HIV-associated gastrointestinal microbial dysbiosis influences the efficacy of anti-HIV immunity by immune checkpoint blockade
by: I.N. SahBandar, et al.
Published: (2017)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma
by: Albert Jang, et al.
Published: (2023)

Biomarkers Associated with Immune Checkpoint, N6-Methyladenosine, and Ferroptosis in Patients with Restenosis
by: Tong X, et al.
Published: (2023)

Focused ultrasound-mediated small-molecule delivery to potentiate immune checkpoint blockade in solid tumors
by: Qiuyu Wu, et al.
Published: (2023)

Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
by: Robert Roskoski, Jr
Published: (2024)

Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy
by: Jingjing Su, et al.
Published: (2024)

Targeting DNA Damage Repair and Immune Checkpoint Proteins for Optimizing the Treatment of Endometrial Cancer
by: Xing Bian, et al.
Published: (2023)

Imaging of Clear Cell Renal Carcinoma with Immune Checkpoint Targeting Aptamer-Based Probe
by: Stanisław Malicki, et al.
Published: (2022)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
by: Amy H. Lin, et al.
Published: (2017)

Immune Checkpoint Inhibitors: Changing the Treatment Landscape in Esophagogastric Adenocarcinoma
by: Emer Lynch, et al.
Published: (2023)

Cardiovascular toxicity profile of immune response checkpoint inhibitors
by: Andrei V. Vazhenin, et al.
Published: (2024)

Local delivery of checkpoints antibodies
by: Chao Wang, et al.
Published: (2017)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
by: Rilan Bai, et al.
Published: (2020)

Association of lichen sclerosus and morphea with immune checkpoint therapy: a systematic review
by: Leah Shin, BA, et al.
Published: (2023)

Immune Checkpoint Molecules and Cancer Immunotherapy
by: Alexandr V. Bazhin
Published: (2019)

Immune Checkpoint in Glioblastoma: Promising and Challenging
by: Jing Huang, et al.
Published: (2017)

The gut microbiota and immune checkpoint inhibitors
by: Audrey Humphries, et al.
Published: (2018)

Cardiovascular complications of immune checkpoint inhibitors
by: A. A. Kulievа, et al.
Published: (2020)